These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19668084)

  • 1. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.
    Moore DM; Harris R; Lima V; Hogg B; May M; Yip B; Justice A; Mocroft A; Reiss P; Lampe F; Chêne G; Costagliola D; Elzi L; Mugavero MJ; Monforte AD; Sabin C; Podzamczer D; Fätkenheuer G; Staszewski S; Gill J; Sterne JA;
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):357-63. PubMed ID: 19668084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts.
    Wright ST; Carr A; Woolley I; Giles M; Hoy J; Cooper DA; Law MG;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):72-9. PubMed ID: 21654498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
    ; Lanoy E; May M; Mocroft A; Phillip A; Justice A; Chêne G; Furrer H; Sterling T; Monforte AD; Force L; Gill J; Harris R; Hogg RS; Rockstroh J; Saag M; Khaykin P; de Wolf F; Sterne JA; Costagliola D
    AIDS; 2009 Oct; 23(16):2199-208. PubMed ID: 19779320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia.
    Chi BH; Giganti M; Mulenga PL; Limbada M; Reid SE; Mutale W; Stringer JS
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):125-31. PubMed ID: 19546812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.
    Hughes RA; Sterne JA; Walsh J; Bansi L; Gilson R; Orkin C; Hill T; Ainsworth J; Anderson J; Gompels M; Dunn D; Johnson MA; Phillips AN; Pillay D; Leen C; Easterbrook P; Gazzard B; Fisher M; Sabin CA
    HIV Med; 2011 Nov; 12(10):583-93. PubMed ID: 21569188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.
    Soeters HM; Sawry S; Moultrie H; Rie AV
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):136-44. PubMed ID: 25072611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
    Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
    JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy.
    Moore DM; Awor A; Downing R; Kaplan J; Montaner JS; Hancock J; Were W; Mermin J
    J Acquir Immune Defic Syndr; 2008 Dec; 49(5):477-84. PubMed ID: 18989232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.
    Nsanzimana S; Remera E; Kanters S; Forrest JI; Ford N; Condo J; Binagwaho A; Bucher H; Thorlund K; Vitoria M; Mills EJ
    Lancet HIV; 2015 Sep; 2(9):e376-84. PubMed ID: 26423551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.
    Loutfy MR; Genebat M; Moore D; Raboud J; Chan K; Antoniou T; Milan D; Shen A; Klein MB; Cooper C; Machouf N; Rourke SB; Rachlis A; Tsoukas C; Montaner JS; Walmsley SL; Smieja M; Bayoumi A; Mills E; Hogg RS;
    J Acquir Immune Defic Syndr; 2010 Dec; 55(4):451-9. PubMed ID: 21105259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.
    Engsig FN; Zangerle R; Katsarou O; Dabis F; Reiss P; Gill J; Porter K; Sabin C; Riordan A; Fätkenheuer G; Gutiérrez F; Raffi F; Kirk O; Mary-Krause M; Stephan C; de Olalla PG; Guest J; Samji H; Castagna A; d'Arminio Monforte A; Skaletz-Rorowski A; Ramos J; Lapadula G; Mussini C; Force L; Meyer L; Lampe F; Boufassa F; Bucher HC; De Wit S; Burkholder GA; Teira R; Justice AC; Sterling TR; M Crane H; Gerstoft J; Grarup J; May M; Chêne G; Ingle SM; Sterne J; Obel N;
    Clin Infect Dis; 2014 May; 58(9):1312-21. PubMed ID: 24457342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.
    Rajasuriar R; Gouillou M; Spelman T; Read T; Hoy J; Law M; Cameron PU; Petoumenos K; Lewin SR
    PLoS One; 2011; 6(6):e20713. PubMed ID: 21674057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
    del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
    Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
    Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
    JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population.
    Zaragoza-Macias E; Cosco D; Nguyen ML; Del Rio C; Lennox J
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):133-8. PubMed ID: 20156096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
    Geretti AM; Harrison L; Green H; Sabin C; Hill T; Fearnhill E; Pillay D; Dunn D;
    Clin Infect Dis; 2009 May; 48(9):1296-305. PubMed ID: 19331585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
    Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
    J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.
    Siegfried N; Davies MA; Penazzato M; Muhe LM; Egger M
    Cochrane Database Syst Rev; 2013 Oct; 10(10):CD010309. PubMed ID: 24114324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.